Forging a position as an innovative player in
infectious disease vaccines and therapies

Announcements

2017

November
20/11/2017 2017 BioDiem AGM CEO Presentation
  Results of 2017 BioDiem AGM
  2017 BioDiem AGM Chairman’s address
10/11/2017 Receipt of 2017 Income Tax Return Refund
October
20/10/2017 BioDiem Annual Report 2017
  BioDiem Notice of Annual General Meeting – Explanatory Statement
July
10/07/2017 BioDiem – OPAL Update and EOFY information
May
22/05/2017 Receipt of 2016 Income Tax Return Refund
March
17/03/2017 BioDiem Releases Half Year Results

2016

October
19/10/2016 2016 BioDiem Results of Meeting
  2016 Chairman’s Address
September
19/09/2016 BioDiem Annual Report 2016
  BioDiem Notice of Annual General Meeting and Proxy form 2016
August
10/08/2016 Completion of Entitlement Offer and Issue of Convertible Preference Shares
June
14/06/2016 BioDiem Entitlement Offer Replacement Prospectus
  Non-renounceable pro rata Entitlement Offer
May
11/05/2016 Results of General Meeting
April
13/04/2016 BDM-I Presentation at European Clinical Conference
08/04/2016 Notice of General Meeting with Proxy
March
31/03/2016 Influenza Vaccine Clinical Trial commences in China
  BioDiem Releases Half Year Results
February
26/02/2016 BioDiem/Opal Biosciences Investor Presentation at Wholesale Investor
January
22/01/2016 Appointment of Prof Li to the BioDiem Board
  Completion of Non-renounceable Entitlement Offer and Issue of Entitlement and Shortfall Shares
  Share Trading Contact Information

2015

December
23/12/2015 Income Tax Return Refund
22/12/2015 Rights Issue Closure and Results
11/12/2015 Further US patent granted for Opal
04/12/2015 BioDiem is presented at Wholesale Investor, Sydney
November
27/11/2015 BioDiem Rights Issue
  BioDiem Entitlement Offer Prospectus
25/11/2015 BioDiem is presented at Wholesale Investor, Melbourne
06/11/2015 New European patents for Opal Biosciences antimicrobial, BDM-I
October
21/10/2015 Nasovac-S WHO PreQualification Certification
19/10/2015 2015 Results of Meeting
  2015 Chairman’s Address to AGM
  2015 AGM CEO Address
  AGM 2015 Presentation
September
24/09/2015 Chinese FDA gives approval to start LAIV vaccine clinical trials
17/09/2015 BioDiem Notice of Annual General Meeting and Proxy form 2015
  BioDiem Annual Report 2015
August
26/08/2015 Opal Update
07/08/2015 Shareholder Update
July
16/07/2015 Opal’s technology presented at the Australian Society for Microbiology Annual Meeting
10/07/2015 Successful grant for BDM-I – Griffith University
07/07/2015 Results of General Meeting
June
17/06/2015 Opal Biosciences’ anti-infective technology profiled at 2015 BIO International Convention
05/06/2015 BioDiem Shareholder Update: Opal Biosciences Ltd.
May
14/05/2015 May 2015 Shareholder Update
March
24/03/2015 Board Announcement – Don Brooks
16/03/2015 BioDiem Half Year Financial Report
February
23/02/2015 Notification of exercise of (8 cent) BioDiem options
January
30/01/2015 Letter to BioDiem option holders
  BioDiem Update
06/01/2015 Notice of extension of exercise period for BioDiem options to 13th February 2015

2014

December
24/12/2014 New Japanese patent for antimicrobial BDM-I
  Professor Arthur Li directorship
05/12/2014 BioDiem CEO appointed Chairman of Ausbiotech
  Wholesale Investor’s Sydney Capital Showcase and Australia Biotech Invest, Melbourne.
02/12/2014 Letter to Optionholders – Upcoming Expiry of 8 cent Options
  December 2014 newsletter
November
10/11/2014 Wholesale Investor – Singapore Capital Expo and Small Cap Showcase Presentation
07/11/2014 Notification of 8 cent Options Expiring 31 December 2014 with attached form
October
23/10/2014 2014 AGM Chairman’s address
  2014 BioDiem AGM CEO presentation
  2014 Results of Meeting
September
30/09/2014 Annual Report 2014
  BioDiem Notice of Annual General Meeting and Proxy form 2014
15/09/2014 BioDiem Full Year Financial Results
June
23/06/2014 ALS Investment Showcase San Francisco presentation 2014
May
29/05/2014 Griffith University’s Industry Fund collaborates in BDM-I screening
April
30/04/2014 Completion of Non-renounceable Entitlement Offer and Issue of Entitlement and Shortfall Shares
  BDM-I antimicrobial – mechanism of action investigation
23/04/2014 Non-Renounceable Entitlement Offer – Closure, Acceptances and Shortfall
10/04/2014 BioDiem Rights Issue Update.
09/04/2014 BioDiem supplementary prospectus
March
20/03/2014 Receipt of R&D Tax incentive payment
18/03/2014 Rights Issue – Replacement Prospectus
  BioDiem Replacement Prospectus
12/03/2014 BioDiem Limited-Half-year Financial Report
04/03/2014 BioDiem Prospectus Update
February
24/02/2014 BioDiem Rights Issue
  BioDiem Ltd prospectus
18/02/2014 Seasonal influenza vaccine using BioDiem’s technology approved for sale in India

2013

December
16/12/2013 Receipt of 2012 Income Tax Return Refund
12/12/2013 Shareholder Update – Delisting and New Issuer Sponsored Holding Statements
05/12/2013 Publication of Research in Journal of Virology
November
15/11/2013 BioDiem removal from ASX official list
07/11/2013 Suspension from Official Quotation 8 November, 2013
October
30/10/2013 Appendix 4C
28/10/2013 Australia Biotech Invest Presentation 2013
25/10/2013 Change of Principal Place of Business and Registered Office
24/10/2013 China Presentation of BioDiem’s Liver Treatment Technology
08/10/2013 2013 Results of Meeting
  AGM CEO Presentation
  Chairmans Address to AGM
September
24/09/2013 BDM WI Capital Showcase Presentation
16/09/2013 BioDiem’s BDM-I presented at international conference
09/09/2013 Appendix 3Y Change of director’s interest notice
06/09/2013 Appendix 3Y Change of Director’s interest notice
  BioDiem Notice of Annual General Meeting and Proxy Form 2013
  Chairmans Letter AGM 2013
  Annual Report 2013
August
30/08/2013 Proposed Delisting from ASX
27/08/2013 Appendix 4E and Statutory Accounts
23/08/2013 BDM-I Third US patent
July
31/07/2013 Appendix 4C
23/07/2013 BDM Presentation to Shareholders Sydney
22/07/2013 Proof of Principle shown in liver disease vaccine program
11/07/2013 Griffith Uni study enhances BioDiem’s antimicrobial program
05/07/2013 BDM Expiry Unlisted Options
June
19/06/2013 BioDiem’s Asia Biotech Invest 2013 video presentation
04/06/2013 Asia Biotech Investor presentation 2013
May
22/05/2013 New Japanese protozal patent for BDM-I
10/05/2013 BDM-I progress in NIH Research Program as Fungal Infection Treatment
April
30/04/2013 Appendix 4C
19/04/2013 ALSIS Investment Showcase NY presentation April 2013
05/04/2013 Van Leeuwenhoeck Research publishes updated analyst report
  Van Leeuwenhoeck Research Full Report
March
20/03/2013 BioPharma Asia Presentation March 2013
February
21/02/2013 Additional Antimicrobial Patent Granted in China
  BioDiem Half Yearly Report and Accounts
14/02/2013 BioDiem extends co-operative agreement with USAMRIID
  Investor Presentation
12/02/2013 Chinese vaccine partner pays annual license fee early
08/02/2013 Progress to POC testing of BDMI effect against parasites
07/02/2013 Change of Registered Office
01/02/2013 BioDiem’s antimicrobial continues in US NIH Research Program
January
31/01/2013 Appendix 4C – quarterly
15/01/2013 BioDiem Update

2012

December
12/12/2012 SII progresses international plans for BioDiem vaccines
November
21/11/2012 Japanese Patent Office to grant BioDiem new patent for BDM-I antimicrobia
20/11/2012 Wholesale Investor Emerging Company Showcase presentation
15/11/2012 Change to Company Secretary
08/11/2012 BDM partners with Griffith University to enhance antimicrobial drug
02/11/2012 Australasian Life Science Investment Summit Presentation
01/11/2012 Replacement Prospectus
  Appendix 3B
October
24/10/2012 Appendix 4C – quarterly
  Extension to closing date for Renounceable Rights Issue
18/10/2012 BDM-I Program Update
15/10/2012 Amendment to Notice of Annual General Meeting
12/10/2012 Annual Report to shareholders
04/10/2012 Letter to Shareholders
01/10/2012 Renounceable Issue Prospectus
September
28/09/2012 Full Year Statutory Accounts
  BioDiem Investor Presentation
  Appendix 3B
  BioDiem Renounceable Rights Issue
August
31/08/2012 Preliminary Final Report
08/08/2012 Successful growth of BioDiem’s Virus in VIVALIS EB66 Cell Line
  BioDiem granted European patent for BDM-I antimicrobial
July
27/07/2012 Appendix 4C – quarterly
23/07/2012 BDM presents findings at international eye research meeting
19/07/2012 BioDiem signs seed development research agreement with RMIT
03/07/2012 BioDiem Company Update
June
29/06/2012 Letter to Shareholders
26/06/2012 BioDiem secures rights to novel Hepatitis technology
25/06/2012 BioDiem signs Dengue Fever agreement with ANU
18/06/2012 Australian Life Science Investment Showcase
06/06/2012 ANU to grant BioDiem exclusive license for novel technology
May
30/05/2012 BioDiem partners with Foundation Fighting Blindness
10/05/2012 BioDiem Option Expiry Notice
09/05/2012 BioDiem LAIV to be tested in French proprietary cell line
08/05/2012 BioDiem receives licence fees for LAIV influenza vaccine
03/05/2012 BDM-I patent position strengthened with new US patent
April
30/04/2012 Appendix 4C – quarterly
23/04/2012 April 2012 Shareholder Update
February
29/02/2012 Half Year Report and Accounts
09/02/2012 BioDiem Licenses LAIV Technology to Changchun BCHT Biotechnology
January
24/01/2012 Appendix 4C – quarterly